The surge in chronic disorders has spurred a heightened demand for effective treatments worldwide. Conditions like anemia, hemophilia, lymphoma, diabetes, leukemia, and the ongoing COVID-19 pandemic collectively contribute to a significant health burden. According to the Center for Disease Control (CDC), data from 2019 indicates that six out of ten adults grapple with chronic diseases, while four out of ten contend with multiple chronic ailments. This statistical insight underscores the escalating burden of diseases and the imperative need for their efficient management.
Anemia, a prevalent condition globally, has a staggering impact, affecting over 1.62 billion individuals, accounting for nearly 24.8% of the world's population, as highlighted by the World Health Organization (WHO). Particularly concerning is its prevalence among women of reproductive age, primarily due to iron deficiency. Women aged 15-49 are notably susceptible, with WHO reports from 2019 indicating that 29.9% within this demographic endure anemia. Moreover, the data highlights a concerning prevalence among children aged 6-59 months, with 39.8% affected globally. In the African region, the impact is notably severe, affecting a staggering 60.2% of children within the same age group.
The burden of anemia extends beyond specific demographics. WHO data points to 539,000 cases of non-pregnant individuals affected by anemia globally. Notably, Southeast Asia stands out, recording the highest number of non-pregnant individuals afflicted by anemia, with figures reaching 234,000 cases. This data underscores the global impact of anemia and its varying prevalence across different demographics and regions.
These statistics illuminate the pervasive impact of chronic diseases like anemia and the substantial burden they pose on global health. Understanding the demographic-specific prevalence is crucial in formulating targeted interventions and strategies to mitigate the impact of these conditions. Addressing the multifaceted challenges posed by chronic disorders demands a concerted effort towards effective management and interventions tailored to diverse populations and regions.
The global surge in various cancer types, including lung, blood, breast, and liver cancers, reflects an alarming trend. GLOBOCAN 2020 estimates from the International Agency for Research on Cancer (IARC) revealed a staggering toll, with approximately 19.3 million new cancer cases and about 10.0 million cancer-related deaths worldwide in 2020. In the United States alone, the National Cancer Institute reported an estimated 1,735,350 new cancer diagnoses and 609,640 deaths in 2018. The trajectory of cancer cases intersects with the impact of the COVID-19 pandemic, further influencing the growth dynamics of the stem cell market.
Looking specifically at blood cancers, the American Cancer Society foresees diagnosing over 186,400 individuals in the US with leukemia, lymphoma, or myeloma by the end of 2021. These specific blood cancer cases are expected to constitute approximately 9.8% of the estimated 1,898,160 new cancer cases projected across the US in 2021. This significant upsurge in blood cancer cases is poised to stimulate the demand for blood grouping reagents on a global scale.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | • Emergence of automated medical devices |
Global Blood Grouping Reagents Market size is projected to be worth USD 0.0020 billion by 2032, registering a CAGR of 7.6% during the forecast period (2023 - 2032), The market was valued at USD 1,578.78 million in 2020.
Blood grouping reagents are solutions that can be used to identify ABO, Rhesus, Kell and MNS blood groups. These classifications of human blood are based on the presence or absence of antigens on the surface of red blood cells. The reagents can affect the agglutination (clumping) on the test red blood cells which transfer antigen. No clumping of the test red blood cells can specify the absence of a certain antigen.
The blood grouping reagents market has been segmented into products, technique, test type, end user, and region. The market is driven by factors such as growing prevalence of chronic disorders and increasing spending in medical research. However, concern pertaining to efficiency and proficiency of test kits hinder the growth of this market.
COVID-19 Analysis
The emergence of coronavirus negatively impacted various sectors across the globe. The healthcare sector was also negatively impacted owing to production restrictions, cessation of clinical trials, and R&D activities. However, the increasing number of COVID-19 patients require blood grouping reagent products on a large scale for diagnostic applications. The increasing number of assay techniques to confirm the presence or absence of coronavirus among patients is creating huge demand across the globe. The sudden surge in diagnostic tests created pressure among the market players to produce blood grouping reagent products. In addition, the rising number of molecular assay tests and RT-PCR tests for confirmation of disease is driving the demand for blood grouping reagent products.
Market Dynamics
Market Restraints
Market Opportunities
Value Chain Analysis
The global blood grouping reagents market is showing significant growth owing to the increasing hereditary disorders, high exposure to chemical toxins, and radioactive materials. The value chain analysis for the market comprises four major components, research & development and product designing, manufacturing, distribution & sales, and post-sales review.
Segment Overview
By Product
Blood grouping reagents include several consumables, including Anti-A, Anti-B, Anti-AB, Anti-D, Anti-D (PK 1), Anti-D (PK 2), control reagents, and phenotyping reagents as Anti-C, Anti-E, Anti-c, Anti-e, Anti-K. Companies such as Merck KGaA, Bio-Rad Laboratories Inc, Novacyt SA, Beckman Coulter, Inc., Grifols SA, Immucor, Inc., among others, offer a wide range of consumables supporting the market demand.
The blood grouping instrument is used to determine blood type by performing ABO grouping, Rh typing, antibody screening, and cross matching tests. These instruments are utilized to analyze the blood groups and offer several benefits over tests performed manually by technicians, such as a reduction in human errors. For instance, the IH-500 system by Bio-Rad Laboratories Inc. (US) incorporates a 6-axis robot transport arm and offers a high level of automation and minimizes user operations.
By Technique
The increasing pace of development in molecular biological techniques has directly affected mass testing and diagnostic applications, including blood screening. Polymerase chain reaction (PCR) and microarray techniques have been successfully applied to blood grouping. PCR-based assays can be used to predict the antigen type of donor RBCs for transfusion and antibody identification reagent panels.
An assay-based technique is an analytic procedure used for blood grouping. Solid-phase assays such as ELISA and bead-based technology, including the Luminex method, are used for blood grouping. Solid-phase assays use reagent antigens or antibodies affixed to a surface (usually a microplate).  Several automated analyzers use solid-phase assays for blood grouping. For instance, Abcam Plc (UK), provides Human ABO ELISA Kit (Histo-Blood Group ABO System Transferase).
Massively parallel sequencing techniques provide a comprehensive blood-group variant profile. However, this technique is dependent on labor-intensive data analysis by experts in blood-group genomics—a lack of trained workforce restraints the growth of this technique.
Serology is an analytic technique used for the diagnostic identification of antibodies in the serum that involves typing for antigens found on the surface of blood cells. However, this technique has certain limitations and cannot respond to the growing demand for blood products type for a large number of antigens. The serology segment is further be sub-segmented into gel technique, erythrocytes magnetized technology (EMT), solid-phase red-cell adherence (SPRCA), glass slide, glass tube, cassette/kits, and others.
The other techniques are expected to register a CAGR of 7.39%.
By Test Type
The phenotype of RBCs refers to determining the type of antigens present on the RBC. The 'type and screen' determines both the ABO-Rh of the patient and screens for the presence of the most commonly found unexpected antibodies. It is performed on all patients requiring transfusions. However, an extended antigen phenotype may also be performed.
The antibody screening is done to check whether an antibody to a red cell antigen has been produced. Antibody screening is performed to detect antibodies in patients requiring blood transfusion, pregnant women, patients with suspected transfusion reactions, and blood and plasma donors.
Crossmatching tests are among the most important serological tests and are performed before a blood transfusion to ensure that the donor blood is compatible. It involves adding the recipient's plasma to the donor blood cells and observing for agglutination reactions.
Antibody identification involves analysis for the presence or absence of a particular antibody (qualitative) or the amount of antibody present (quantitative). The antibody identification testing is done for several applications, including documenting exposure to an infectious or foreign agent, evaluating immune status against a particular microorganism, diagnosing an autoimmune condition, diagnosing the reason for a transfusion reaction or a rejection of a transplanted organ, diagnosing an allergy, and monitoring the course of an infection or autoimmune process.
A Coombs test, also known as antiglobulin test, is either of two blood tests used in immunohematology. They are the direct and indirect Coombs tests. A direct Coombs test is performed to detect if antibodies are bound to red blood cells inside the person's body, which is abnormal and can occur in conditions like autoimmune hemolytic anemia, hemolytic disease of the newborn and transfusion reactions. The indirect Coombs test is used to screen for antibodies that could cause transfusion reactions and identify certain blood group antigens.
Antigen typing is performed if patients are found with clinically significant autoantibodies. The procedure is performed for the corresponding antigens to confirm if the antibodies are alloantibodies or autoantibodies. Also, if such a patient requires blood transfusion, all donor units to be crossmatched are antigen typed.
By End User
A person usually visits a clinic or hospital to find out their blood type. In clinics and hospitals, a doctor or nurse draws a blood sample and sends it to a lab for testing. Hospital-based laboratories are attached to the hospital, and the laboratory staff are employed by the hospital. These laboratories perform laboratory testing for inpatients and outpatients.
Blood banking tasks primarily include collecting, processing, testing, storing, and distributing whole blood and blood products. According to the American National Red Cross, about 6.8 million people in the US donate blood each year. A certain set of standard tests are done in the lab once blood is donated, including ABO grouping and Rh typing.
Clinical laboratories are independent organizations or companies that test the product and material according to the requirements. The testing carried out by independent laboratories is known as "third-party" testing. These clinical laboratories offer advanced testing services and potentially provide a cost-saving alternative to hospitals and clinics lacking the infrastructure.
Regional Analysis
GLOBAL BLOOD GROUPING REAGENTS MARKET SHARE (%), BY Region, 2020Source: MRFR analysis
North America
North America dominated the global blood grouping market due to the presence of major manufacturers, increasing prevalence of chronic diseases leading to the high demand for blood transfusion and organ transplant
The key factors such as presence of major manufacturers, increasing prevalence of chronic diseases leading to the high demand for blood transfusion and organ transplant, technological advancements in the clinical segment, and increasing awareness among the population are expected to drive market growth. The key manufacturers are anticipated to launch new products, collaborate for optimization of the cash flow channel, and partially outsource the production process. Moreover, increasing investments in research and collaborative approach to improve the technology for blood grouping in the region is anticipated to increase the market size over the forecast period.
Asia-Pacific
Asia-Pacific presents lucrative opportunities for players operating in the blood grouping reagents market
The blood grouping reagents market in Asia-Pacific is expected to be the fastest-growing regional market. Key factors that influence the markets growth include the growing incidence of traumatic injuries from accidents and trauma in the region. Increasing demand for blood banking services, government initiatives and increasing public awareness about blood donation are driving the markets growth in this region. Globally, road accidents are the tenth leading cause of death. India accounted for about 500,000 road accidents in 2019, one of the highest in the world, in which about 150,000 people die and another 300,000 became crippled. In 2018, India had 467,044 reported road accidents, an increase of 0.5% from 464,910 in 2017, according to the road ministry's data. Moreover, in 2018, 63,194 traffic accident fatalities were recorded by China's National Bureau of Statistics. Many road accidents causing traumatic injuries are anticipated to increase the demand for blood grouping reagents in the region.
Competitive Landscape
The global blood grouping reagents market is expected to grow significantly in the coming years due to the increasing chronic diseases across the globe. The global blood grouping reagents market is characterized by the presence of several global, regional, and local vendors. The market is highly competitive, with all the players trying to gain maximum market share. Frequent changes in government policies, intense competition, and FDA regulations are the key factors that impact global market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services. It is crucial for the players to offer cost-efficient and high-quality blood grouping reagents products to succeed in an intensely competitive market environment.
List of companies with HQ
Recent Developments
Report Overview
The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.
Study Objectives
Market Segmentation:
Global Blood Grouping Reagents Market, By Product
Global Blood Grouping Reagents Market, By Technique
Global Blood Grouping Reagents Market, By Test Type
Global Blood Grouping Reagents Market, By End User
Global Blood Grouping Reagents Market, By Region
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)